Semin Liver Dis 2019; 39(03): 341-353
DOI: 10.1055/s-0039-1685538
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Long-Term Impact of Direct-Acting Antiviral Agent Therapy in HCV Cirrhosis: Critical Review

Sasha R. Fehily
1   Department of Gastroenterology, St Vincent's Hospital, University of Melbourne, Victoria, Australia
,
Tim Papaluca
1   Department of Gastroenterology, St Vincent's Hospital, University of Melbourne, Victoria, Australia
,
Alexander J. Thompson
1   Department of Gastroenterology, St Vincent's Hospital, University of Melbourne, Victoria, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
30 April 2019 (online)

Abstract

More than 70 million people are chronically infected with hepatitis C virus (HCV) worldwide. Chronic hepatitis C is associated with progressive liver fibrosis, which can result in cirrhosis, liver failure, and hepatocellular carcinoma (HCC). HCV-related liver disease has been the most common indication for liver transplantation in the past decade. The development of direct-acting antiviral agents (DAAs) that are simple, well-tolerated, and highly effective means that most people living with hepatitis C can now be cured, leading the World Health Organization to set targets for reduction in deaths due to viral hepatitis by 2030. In this review, the authors will consider the emerging data showing that curative therapy with DAAs can prevent HCV-related morbidity and mortality, with a focus on patients with HCV-related cirrhosis.

 
  • References

  • 1 Blach S, Zeuzem S, Manns M. , et al; Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2 (03) 161-176
  • 2 Graziadei I, Zoller H, Fickert P. , et al. Indications for liver transplantation in adults : recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). Wien Klin Wochenschr 2016; 128 (19-20): 679-690
  • 3 Goldberg D, Ditah IC, Saeian K. , et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 2017; 152 (05) 1090-1099.e1
  • 4 World Health Organization. Global Health Sector Strategy on Viral Hepatitis: 2016–2021. 2016 . Available at: http://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=2F25735A1136EE7724562722A78A4734?sequence=1 . Accessed August 3, 2018
  • 5 Younossi ZM, Stepanova M, Nader F. , et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology 2014; 59 (06) 2161-2169
  • 6 Younossi ZM, Kanwal F, Saab S. , et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 2014; 39 (05) 518-531
  • 7 Younossi ZM, Stepanova M, Henry L. , et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014; 12 (08) 1349-59.e13
  • 8 Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014; 60 (03) 530-537
  • 9 Younossi ZM, Stepanova M, Marcellin P. , et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology 2015; 61 (06) 1798-1808
  • 10 Younossi ZM, Stepanova M, Afdhal N. , et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 2015; 63 (02) 337-345
  • 11 Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 2016; 150 (07) 1599-1608
  • 12 Younossi ZM, Stepanova M, Feld J. , et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol 2016; 65 (01) 33-39
  • 13 Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (05) (Suppl. 01) S35-S46
  • 14 Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48 (02) 418-431
  • 15 Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 2014; 60 (01) 98-105
  • 16 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349 (9055): 825-832
  • 17 Benhamou Y, Bochet M, Di Martino V. , et al; The Multivirc Group. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999; 30 (04) 1054-1058
  • 18 Massard J, Ratziu V, Thabut D. , et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44 (1, Suppl): S19-S24
  • 19 Muzzi A, Leandro G, Rubbia-Brandt L. , et al; Swiss Hepatitis C Cohort Study. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005; 42 (01) 41-46
  • 20 Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99 (06) 1160-1174
  • 21 Dienstag JL, Ghany MG, Morgan TR. , et al; HALT-C Trial Group. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011; 54 (02) 396-405
  • 22 Aghemo A, Lampertico P, Colombo M. Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense. J Hepatol 2012; 57 (06) 1326-1335
  • 23 Foster GR, Afdhal N, Roberts SK. , et al; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373 (27) 2608-2617
  • 24 American Association for the Study of Liver Diseases. Hepatology. Available at: https://www.aasld.org/publications . Accessed August 3, 2018
  • 25 European Association for the Study of the Liver. EASL Clinical Practice Guidelines. Available at: http://www.easl.eu/research/our-contributions/clinical-practice-guidelines . Accessed September 27, 2018
  • 26 Gastroenterological Society of Australia. Hepatitis C Treatment. Available at: http://www.gesa.org.au/resources/hepatitis-c-treatment/ . Accessed August 3, 2018
  • 27 Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Med J Aust 2016; 204 (07) 268-272
  • 28 World Health Organization. Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection. Geneva: World Health Organization; 2018: 108
  • 29 Chen J, Florian J, Carter W. , et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144 (07) 1450-1455.e2
  • 30 Cozen ML, Ryan JC, Shen H. , et al. Improved survival among all interferon-α-treated patients in HCV-002, a Veterans Affairs hepatitis c cohort of 2211 patients, despite increased cirrhosis among nonresponders. Dig Dis Sci 2016; 61 (06) 1744-1756
  • 31 Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9 (06) 509-516.e1
  • 32 Buti M, San Miguel R, Brosa M. , et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005; 42 (05) 639-645
  • 33 Fernández-Rodríguez CM, Alonso S, Martinez SM. , et al; Group for the Assessment of Prevention of Cirrhosis Complications and Virological Response (APREVIR). Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol 2010; 105 (10) 2164-2172 , quiz 2173
  • 34 Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138 (02) 513-521 , 521.e1–521.e6
  • 35 Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9 (11) 923-930
  • 36 Cheung MC, Walker AJ, Hudson BE. , et al; HCV Research UK. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016; 65 (04) 741-747
  • 37 van der Meer AJ, Veldt BJ, Feld JJ. , et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308 (24) 2584-2593
  • 38 Bruno S, Di Marco V, Iavarone M. , et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol 2016; 64 (06) 1217-1223
  • 39 Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis 2015; 61 (05) 730-740
  • 40 Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis 2015; 15: 19
  • 41 Hill AM, Saleem J, Heath KA, Simmons B. Effects of sustained virological response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 23,309 patients with hepatitis C infection: 44. Hepatology 2014; 60: 218A-219A
  • 42 Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 2013; 158 (02) 114-123
  • 43 Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology 2017
  • 44 Backus LI, Belperio PS, Shahoumian TA, Mole LA. Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease. Hepatology 2018; 68 (03) 827-838
  • 45 Nahon P, Bourcier V, Layese R. , et al; ANRS CO12 CirVir Group. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017; 152 (01) 142-156.e2
  • 46 Nahon P, Lescat M, Layese R. , et al; ANRS CO12 CirVir and Microcir Groups. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort). Gut 2017; 66 (02) 330-341
  • 47 Mandorfer M, Kozbial K, Schwabl P. , et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 2016; 65 (04) 692-699
  • 48 Afdhal N, Everson GT, Calleja JL. , et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat 2017; 24 (10) 823-831
  • 49 Lens S, Alvarado-Tapias E, Mariño Z. , et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology 2017; 153 (05) 1273-1283.e1
  • 50 Lens S, Rincón D, García-Retortillo M. , et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin Gastroenterol Hepatol 2015; 13 (10) 1846-1853.e1
  • 51 World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Available at: https://apps.who.int/iris/bitstream/handle/10665/273174/9789241550345-eng.pdf?ua=1 . Accessed September 4, 2018
  • 52 Curry MP, O'Leary JG, Bzowej N. , et al; ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373 (27) 2618-2628
  • 53 Curry MP, Forns X, Chung RT. , et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148 (01) 100-107.e1
  • 54 Lawitz E, Poordad F, Gutierrez JA. , et al. SVR12 results from the Phase Ii, open-label . IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and-experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease: 39. Hepatology 2015; 62: 227A
  • 55 Martini S, Donato MF, Mazzarelli C. , et al. The Italian Compassionate use of Sofosbuvir (ITACOPS) in patients with HCV-related cirrhosis waitlisted for liver transplantation: virological and clinical outcomes from a national real-life experience.: LB-26. Hepatology 2015; 62 (06) 1395A-1396A
  • 56 Mccaughan G, Roberts S, Strasser S. , et al. The Toscar study: sofosbuvir and daclatasvir therapy for decompensated HCV cirrhosis with MELD scores≥ 15. J Gastroenterol Hepatol 2015; 30: 89
  • 57 Welzel T, Herzer K, Ferenci P. , et al. P0772: Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: Interim results of a multicenter compassionate use program. J Hepatol 2015; 62: S619-S20
  • 58 Gane EJ, Hyland RH, An D. , et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 2015; 149 (06) 1454-1461.e1
  • 59 Manns M, Samuel D, Gane EJ. , et al; SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016; 16 (06) 685-697
  • 60 Foster GR, Irving WL, Cheung MC. , et al; HCV Research, UK. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016; 64 (06) 1224-1231
  • 61 Crespo G, Trota N, Londoño M-C. , et al. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. J Hepatol 2018; 69 (01) 11-17
  • 62 Pascasio JM, Vinaixa C, Ferrer MT. , et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol 2017; 67 (06) 1168-1176
  • 63 Cholankeril G, Ahmed A. Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States. Clin Gastroenterol Hepatol 2018; 16 (08) 1356-1358
  • 64 Belli LS, Berenguer M, Cortesi PA. , et al; European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol 2016; 65 (03) 524-531
  • 65 Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology 2017; 65 (03) 804-812
  • 66 Belli LS, Perricone G, Adam R. , et al; all the contributing centers ( www.eltr.org ) and the European Liver and Intestine Transplant Association (ELITA). Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR Registry. J Hepatol 2018; 69 (04) 810-817
  • 67 Coilly A, Pageaux GP, Houssel-Debry P. , et al. Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAA? 95. Hepatology 2015; 62: 257A
  • 68 Burra P, De Martin E, Zanetto A. , et al. Hepatitis C virus and liver transplantation: where do we stand?. Transpl Int 2016; 29 (02) 135-152
  • 69 Pawlotsky J-M, Negro F, Aghemo A. , et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018; 69 (02) 461-511
  • 70 Panel AIHG, Chung RT, Davis GL. , et al; AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62 (03) 932-954
  • 71 El-Sherif O, Jiang ZG, Tapper EB. , et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology 2018; 154 (08) 2111-2121.e8
  • 72 Charlton M, Everson GT, Flamm SL. , et al; SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149 (03) 649-659
  • 73 Poordad F, Schiff E, Vierling J. , et al. LO8: Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: phase 3 ALLY-1 study. J Hepatol 2015; 62: S261-S2
  • 74 Reau N, Kwo P, Rhee S. , et al. MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1–6 infection. J Hepatol 2017; 66 (01) S90-S1
  • 75 Saadoun D, Thibault V, Si Ahmed SN. , et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis 2016; 75 (10) 1777-1782
  • 76 Sise ME, Bloom AK, Wisocky J. , et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 2016; 63 (02) 408-417
  • 77 Bonacci M, Lens S, Londoño M-C. , et al. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol 2017; 15 (04) 575-583.e1
  • 78 Comarmond C, Garrido M, Pol S. , et al. Direct-acting antiviral therapy restores immune tolerance to patients with hepatitis C virus-induced cryoglobulinemia vasculitis. Gastroenterology 2017; 152 (08) 2052-2062.e2
  • 79 Emery JS, Kuczynski M, La D. , et al. Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia. Am J Gastroenterol 2017; 112 (08) 1298-1308
  • 80 Gragnani L, Piluso A, Urraro T. , et al. Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study. Curr Drug Targets 2017; 18 (07) 772-785
  • 81 Saadoun D, Pol S, Ferfar Y. , et al. Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology 2017; 153 (01) 49-52.e5
  • 82 Lim LY, La D, Cserti-Gazdewich CM, Shah H. Lymphoma remission by interferon-free HCV eradication without chemotherapy. ACG Case Rep J 2015; 3 (01) 69-70
  • 83 Sultanik P, Klotz C, Brault P, Pol S, Mallet V. Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood 2015; 125 (15) 2446-2447
  • 84 Arcaini L, Besson C, Frigeni M. , et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood 2016; 128 (21) 2527-2532
  • 85 Persico M, Aglitti A, Caruso R. , et al. Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma. Hepatology 2018; 67 (01) 48-55
  • 86 Bonacci M, Lens S, Mariño Z. , et al. Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure. Gastroenterology 2018; 155 (02) 311-315.e6
  • 87 Montero N, Favà A, Rodriguez E. , et al. Treatment for hepatitis C virus-associated mixed cryoglobulinaemia. Cochrane Database Syst Rev 2018; 5 (05) CD011403
  • 88 Thompson AJ, Patel K, Chuang W-L. , et al; ACHIEVE-1 and ACHIEVE-2/3 Study Teams. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut 2012; 61 (01) 128-134
  • 89 Hernandez R, Millan R, Sánchez Y. , et al. Effect of hepatitis C sustained virological response on the endothelial dysfunction and the cardiovascular risk. HepCAR study. J Hepatol 2018; 68: S540-S1
  • 90 Petta S, Adinolfi LE, Fracanzani AL. , et al. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol 2018; 69 (01) 18-24
  • 91 Drazilova S, Gazda J, Janicko M, Jarcuska P. Chronic hepatitis C association with diabetes mellitus and cardiovascular risk in the era of DAA therapy. Can J Gastroenterol Hepatol 2018; 2018: 6150861
  • 92 Singer A, Osinusi AO, Brainard D, Telep L, Chokkalingam A. , eds. Risk of Incident Diabetes in Hepatitis C Patients following Completion of Direct-Acting Antiviral Therapy. Hoboken, NJ: Wiley; 2018
  • 93 Mauss S, Petersen J, Witthoeft T. , et al. Sustained responders have lower rates of liver-related events and a better quality of life and productivity compared with non-responders/relapsers after antiviral treatment of chronic hepatitis C: 800. Hepatology 2012; 56: 582A-583A
  • 94 John-Baptiste AA, Tomlinson G, Hsu PC. , et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 2009; 104 (10) 2439-2448
  • 95 Richmond JA, Ellard J, Wallace J. , et al. Achieving a hepatitis C cure: a qualitative exploration of the experiences and meanings of achieving a hepatitis C cure using the direct acting antivirals in Australia. Hepatol Med Policy 2018; 3 (01) 8
  • 96 Madden A, Hopwood M, Neale J, Treloar C. Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia. Harm Reduct J 2018; 15 (01) 42
  • 97 Karatzas A, Konstantakis C, Aggeletopoulou I, Kalogeropoulou C, Thomopoulos K, Triantos C. Non-invasive screening for esophageal varices in patients with liver cirrhosis. Ann Gastroenterol 2018; 31 (03) 305-314
  • 98 Ding NS, Nguyen T, Iser DM. , et al. Liver stiffness plus platelet count can be used to exclude high-risk oesophageal varices. Liver Int 2016; 36 (02) 240-245
  • 99 World Health Organization. Combating Hepatitis B and C to Reach Elimination by 2030: Advocacy Brief. Geneva, Switzerland: World Health Organization; 2016
  • 100 Nelson PK, Mathers BM, Cowie B. , et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378 (9791): 571-583
  • 101 Leclerc P, Morissette C, Roy É. Le volet montréalais du Réseau SurvUDI: Données au 30 juin 2007: Agence de la santé et des services sociaux de Montréal, Direction de la santé publique, Secteur vigie et protection; 2008
  • 102 Razavi H, Waked I, Sarrazin C. , et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 (Suppl. 01) 34-59
  • 103 Browne AJ, Varcoe CM, Wong ST. , et al. Closing the health equity gap: evidence-based strategies for primary health care organizations. Int J Equity Health 2012; 11 (01) 59
  • 104 Scott N, Doyle JS, Wilson DP. , et al. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Int J Drug Policy 2017; 47: 107-116
  • 105 Olafsson S, Tyrfingsson T, Runarsdottir V. , et al. Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents. J Intern Med 2018; 283 (05) 500-507
  • 106 Cousien A, Leclerc P, Morissette C. , et al. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study. BMC Infect Dis 2017; 17 (01) 162
  • 107 Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. Lancet Infect Dis 2018; 18 (02) 215-224
  • 108 Martin NK, Vickerman P, Dore GJ. , et al; STOP-HCV Consortium. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. J Hepatol 2016; 65 (01) 17-25
  • 109 Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015; 163 (03) 215-223
  • 110 Stone J, Martin NK, Hickman M. , et al. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction 2017; 112 (07) 1302-1314
  • 111 Dolan K, Wirtz AL, Moazen B. , et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet 2016; 388 (10049): 1089-1102
  • 112 Papaluca T, Thompson A. HCV elimination: breaking down the barriers to prison based care. Hepatoma Res 2018; 4: 64
  • 113 Scott N, McBryde ES, Thompson A, Doyle JS, Hellard ME. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model. Gut 2017; 66 (08) 1507-1515